Take a look at the July issue of Experimental Hematology!

Explore the latest findings, innovative studies and thought-provoking insights that continue to shape the field! Read the July Issue on ExpHem. 

Explore this Issue's Lineup:

MYC unchained: dosage-dependent locking of the myeloid fate (or not)

Alessandro Donada

MYC overexpression is a crucial element of acute myeloid leukemia (AML) physiopathology. By advanced cellular modeling and molecular analysis, Stokes and colleagues showed that MYC overexpression induces a myeloid block. Sustained expression of this oncogene is required and sufficient to maintain the block, a feature shared by multiple AML subtypes. Read more>

A roadmap for systematic humanization of a chimeric antigen receptor: preclinical validation of a humanized CD22 scFv as a model

Narcís Fernández, Paolo Petazzi, Vladimir Mulens-Arias, Laura García Pérez, Pablo Menéndez, Víctor M. Díaz

Open Access

We developed a structure-guided humanization strategy for CD22-targeted chimeric antigen receptor (CAR) T cells that preserves antigen binding while reducing immunogenicity. By grafting murine complementarity-determining regions onto human frameworks and eliminating structural liabilities through in silico and biophysical screening, the resulting CARs maintained specificity and potency in vitro and in vivo, establishing a robust pipeline for next-generation CAR-T design. Read more>

SiglecF-expressing neutrophils differentiate from mature neutrophils locally in the heart after myocardial infarction

Jonah K. Stephan, Taylor Knerr, William S. Isaacs, Yibing Nong, Marcin Wysoczynski

Open Access

Myocardial infarction provokes neutrophil infiltration and the emergence of a SiglecFPos subset. Using in vivo 5-ethynyl-2′-deoxyuridine (EdU) labeling and in vitro assays, we demonstrated that SiglecF is acquired by circulating mature neutrophils within the infarcted myocardium, rather than by local maturation of immature precursors. Granulocyte colony-stimulating factor (G-CSF) and emergency granulopoiesis prime neutrophils with an enhanced capacity to upregulate SiglecF, highlighting a stress-induced program that reshapes neutrophil fate and function after cardiac injury. Read more>

Stem11 score: toward rapid clinical prognostication for acute myeloid leukemia

Tomoya Isobe, Manja Meggendorfer, Sebastian Wolf, Thomas Oellerich, Nicola K. Wilson, Berthold Göttgens

Open Access

Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by aberrant proliferation and differentiation arrest of myeloid progenitor cells. Although genomics-based classification has improved prospective survival prediction, considerable heterogeneity in clinical outcomes persists even within the established genetic risk groups, highlighting the need for additional molecular markers to further refine patient risk stratification. Read more>

Serum cholesterol levels demonstrate dynamic changes following autologous hematopoietic stem cell transplantation in patients with multiple myeloma

Yuan Chen, Shan Gao, Xin Zhao, Weikai Hu, Li Bao

Open Access

Is blood cholesterol a gauge for myeloma relapse? A landmark study shows that with remission, cholesterol levels promptly rise, only to markedly drop on the cancer’s recurrence—unveiling a straightforward new approach to disease tracking. Read more>

The rise of bone marrow organoids as next-generation models for blood formation and failure

Anne Stolz, Lauren M. Harmon, Jingjing Li,...Vu L. Tran, Abdullah Khan, Christoph Klein

Open Access

Bone marrow organoids (BMOs) are three-dimensional cell culture models that mimic the architecture, cellular diversity, and function of the bone marrow niche. Offering a scalable, cost-effective alternative to animal models, BMOs enable personalized disease modeling and drug testing using patient-derived induced pluripotent stem cells and are compatible with gene editing. Recent studies have established protocols and validated applications of BMOs in modeling inflammatory responses, rare bone marrow failure syndromes, and multiple myeloma, highlighting their transformative potential in hematopoietic research. Read more>

Inhibition of activated protein C anticoagulant function enhances coagulation but does not interrupt downstream mechanisms driving hemophilic arthropathy

Clotilde Martin, Leonard A. Valentino, Salomé Farny-Quentin, Alexandre Leuci, Yesim Dargaud

Recurrent hemarthroses in hemophilia drive progressive joint damage in which activated protein C (APC) may play a deleterious role. In a murine model of hemophilic arthropathy, we compared systemic inhibition of APC anticoagulant activity with standard factor VIII prophylaxis for joint protection. Although both strategies effectively reduced joint bleeding, APC inhibition did not confer superior preservation of cartilage or bone compared with FVIII replacement. These findings suggest that systemic APC modulation alone is insufficient to improve joint outcomes beyond current prophylaxis and highlight the need for approaches targeting APC activity directly within the joint microenvironment.

Read more>

Hematopoietic stem cell senescence and opportunities for intervention

Aditya Barve, Preeti Dabas, Terri Cain, Shannon McKinney-Freeman

Cellular senescence is a fundamental stress response program involved in embryonic development, wound healing, immunity, disease pathologies, and aging, which alongside apoptosis, serves as a protective safeguard that enforces cell-cycle exit of damaged cells at risk for malignant transformation [1]. Cellular senescence was first observed and defined by Hayflick and Moorhead [2] in the 1960s and referred to the “limited division capacity” or eventual irreversible growth and proliferation arrest of primary human cells following prolonged replicative culture in vitro. Read more>

A function-first legacy in hematopoietic stem cell biology: the scientific impact of Hal E. Broxmeyer

Xuepeng Wang, Jim Patrick Ropa, Maegan Lynn Capitano, Reuben Kapur

Hal E. Broxmeyer transformed hematopoietic stem cell biology by insisting that stem and progenitor cells be judged by durable, multilineage function rather than phenotype alone. This tribute highlights his function-first legacy across cytokine regulation, umbilical cord blood transplantation, stem cell mobilization, DPP4/CD26-mediated homing and engraftment, and oxygen stress biology, emphasizing how his work linked mechanistic discovery to transplantation-relevant outcomes and enduring clinical practice.

Read more>

New Incentives for Publishing in ExpHem

We're excited to announce a new submission incentivization program!

The first 20 authors after 25 July 2026 with an accepted, eligible manuscript* in ExpHem will receive a $650 discount that can be applied toward a future ISEH Annual Scientific Meeting registration and/or a future ISEH membership.

See program eligibility and guidelines>

*Eligible article types include: the new Standards in Hematology and ExpHem Insights, as well as both Standard and Fast-track original research papers and Brief Communications.

Publish your research in Experimental Hematology and take advantage of our new author incentive program!